Roche announces launch of the FLOW System for Laboratory Developed Testing
PLEASANTON, California, Dec. 16, 2013
-- Comprehensive offering enables standardized workflows with improved
convenience and data automation for laboratories with a high volume of
laboratory developed tests
PLEASANTON, California, Dec. 16, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG;
OTCQX: RHHBY) today announced the launch of its new FLOW system for use with
Laboratory Developed Tests (LDT) in Europe, Asia Pacific, Africa and Latin
America.* This user defined system offers full flexibility along the entire
workflow chain, from primary sample handling to qPCR result analysis. The
system has a broad range of laboratory applications in virology and
microbiology. In addition, Roche's comprehensive offering of reagents,
controls and assays designed and optimized to work on the FLOW
instrumentation, brings a new level of convenience and standardization to
laboratories who run a large volume of LDTs.
The workflow standardization and data automation enabled by FLOW is designed
for applications typically required in laboratories performing laboratory
developed testing with diverse molecular test menus, high sample numbers and
large target variety. FLOW's software seamlessly connects all process steps,
allowing for a new standard of result reliability and reproducibility and
provides full traceability of data and direct communication to the laboratory
information system (LIS).
"We were impressed by the flexibility FLOW offers to our applications and
needs," said Kurt Handberg, Clinical Microbiology Department, Aarhus
University Hospital, Skejby, Denmark. "FLOW is an open system, enabling us to
apply our own in-house assays. In addition, it clearly improved the
traceability of our qPCR testing results while reducing repetitive workload of
"Customers with high throughput LDT applications need high result reliability,
which is improved with the workflow automation," said Paul Brown, Head of
Roche Molecular Diagnostics. "With the launch of FLOW, we can enhance
automation in the LDT setting with the first IT-supported, sample-to-result
qPCR workflow solution built on our well-established technologies and systems.
To date, we have received very positive feedback from pilot users in European
countries highlighting the increased result reliability."
The FLOW system will be immediately available in Europe, Asia Pacific, Africa
and Latin America.
*The FLOW System is not available in the US and other territories.
The FLOW System is a non-IVD system for general laboratory use consisting of 5
components: 1) FLOW Software, 2) FLOW Primary Sample Handling System, 3) MagNA
Pure 96 System for automated nucleic acid purification, 4) FLOW PCR Set Up
System, and 5) the LightCycler® 480 System for amplification. FLOW Software is
able to communicate with the customer's laboratory information system (LIS),
receiving sample and associated analysis request information to generate work
lists. For more information, please visit www.flow.roche.com .
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com .
LIGHTCYCLER and MAGNA PURE are trademarks of Roche.
All other product names and trademarks are the property of their respective
For further information please contact:
Press spacebar to pause and continue. Press esc to stop.